Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01687595 · ClinicalTrials.gov registry record · Phase 2
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
A Phase 2 study, sponsored by Agenus.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT01687595 is a Phase 2 study that has completed, run by Agenus. The registered enrollment target is 80 participants.
The verdict
NCT01687595, a Phase 2 study, has completed, sponsored by Agenus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of recombinant human heat shock protein 70-polyvalent peptide complex (HerpV) vaccine administration on recurring episodes of genital herpes by evaluating viral shedding before and after treatment.
Interventions
- DRUG Placebo
- DRUG HerpV and QS-21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2012-10-29 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01687595
The ClinicalTrials.gov registry entry for NCT01687595 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01687595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01687595 about?
NCT01687595 is a clinical study titled "Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes". The purpose of this study is to evaluate the effect of recombinant human heat shock protein 70-polyvalent peptide complex (HerpV) vaccine administration on recurring episodes of genital herpes by evaluating viral shedding before and after treatment.
What is the current status of trial NCT01687595?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2012-10-29. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01687595?
The interventions under investigation include: Placebo (DRUG), HerpV and QS-21 (DRUG).
Who is sponsoring clinical trial NCT01687595?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.